 |

The Pathogenesis of Diabetic Nephropathy CME DisclosuresRelease Date: July 10, 2008; Valid for credit through July 10, 2009 | | Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians |  | 
| Contents of This CME Activity |  |
 | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.
- The Pathogenesis of Diabetic Nephropathy
Suma Dronavalli, MD Irena Duka, MD George L. Bakris, MD
Go to Test Questions |
| Legal Disclaimer |  |
 | The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
 |

Learning Objectives Upon completion of this activity, participants will be able to: - Describe the epidemiology of diabetic nephropathy
- Explain how hyperglycemia promotes nephropathy
- Identify the roles of prorenin and cytokines in the promotion of diabetic nephropathy
- Describe the
role of nephrin in diabetic nephropathy
Authors and Disclosures
|
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
 |